Вакцинация против болезни Лайма: литература
Appel MJG, Allan S, Jacobson RH, Lauderdale T-L, et al: Experimental Lyme disease in dogs produces arthritis and persistent infection. J Infect Dis 167:651,1993. A general description of the biology of canine Lyme's disease under experimental conditions.
Chang Y-F, Appel MJG, Jacobson RH, et al: Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect Immun 63:3543, 1995. A report of a study in dogs vaccinated with OspA and protected from infection.
Chu H-J, Chavez LG Jr, Blumer BM, Sebring RW, et al: Immunogenicity and efficacy study of a commercial Borrelia burgdorferi bacterin. J Am Vet Med Assoc 201:403,1992. A report of a study in dogs vaccinated with a whole cell bacterin and protected from disease.
Coughlin RT, Fish D, Mather TN, et al: Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp)A, OspB, and the saponin adjuvant QS21. J Infect Dis 171:1049, 1995. A report of a study in dogs vaccinated with OspA and protected from infection.
Levy SA, Barthold SW, Dombach DM, et al: Canine Lyme borreliosis. Comp Cont Ed 15:833,1993. A general description of the biology of canine Lyme's disease under natural conditions.
Lim LCL, England DM, DuChateau BK, et al: Development of destructive arthritis in vaccinated hamsters challenged with B. burgdorferi. Infect Immun 62:2825, 1994. A study in hamsters that developed arthritis after vaccination with whole cell bacterin followed by challenge with live B. burgdorferi.
Lovrich SD, Callister SM, Lim LCL, et al: Seroproteetive groups of Lyme borreliosis spirochetes from North America and Europe. J Infect Dis 170:115, 1994. A report of five distinct seroproteetive groups of B. burgdorferi from North America and Europe.
Straubinger RK, Chang Y-F, Jacobson RH, et al: Sera from OspAvaccinated dogs, but not those from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi. J Clin Microbiol 33:2745, 1995. A description of an assay that detects high levels of borreliacidal antibody in OspA vaccinated dogs and low levels in tick exposed dogs.
Van Hoecke C, Comberbach M, De Grave D, et al: Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults. Vaccine 14:1620,1996.
Wilske B, Busch U, Fingerle V, Jauris-Heipke S, et al: Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development. Infection 24:208, 1996. A description of the variability of OspA and OspC from different isolates of B. burgdorferi.
Wormser GP: Prospects for a vaccine to prevent Lyme disease in humans. Clin Infect Dis 21:1267, 1995. A discussion of the potential of OspA as a human vaccine.
